top of page

The Company Adds Top California Cannabis Strategist Gaynell Rogers to Advisory Board

Boustead Securities client, Resonate Blends, Inc. (OTCQB:KOAN), a cannabis-based holding company (“Resonate” or the “Company”), announced it's launching the industry’s first line of THC-based Koan Cordials.

Koan Cordials (www.koan.life) is slated to ship in first quarter of next year and features 6 cannabis experience-based Cordial products.

Cordials are uniquely formulated, single serving, precisely targeted experiences that are directly ingested or mixed with a drink of your choice for use in social or private settings. Cordials are the first of a family of cannabis products targeting the Wellness Lifestyle market that Resonate is designing under the brand name KOAN®.


The early success of Resonate's 506(c) offering has provided sufficient capital for its launch.


  • The Company has signed and announced definitive agreements with various partners to execute on its overall business strategy, including Vertosa, the Hive Laboratory, and Way To Blue.


  • Gaynell Rogers has joined Resonate on its Advisory Board responsible for strategic outreach with key influencers, creative distribution initiatives and fundraising opportunities through her extensive network. Gaynell is a pioneer in the California cannabis community. As a trusted, established source for major U.S. and international media networks, Gaynell has propelled numerous cannabis companies into the spotlight. As head of Media Relations & Management for Harborside (one of California’s most noted cannabis retailer voted “best dispensary in the state”, she helped its visionary founder Steve DeAngelo gain national notice through Harborside’s first-time front page coverage in major dailies such as The New York Times and The Washington Post.


  • The Company aims to introduce a new product segment every 6 to 8 months built around their proprietary Resonate System.


  • The Company plans to launch an e-commerce storefront and home delivery of their cannabis products. They have also targeted top-end dispensaries in California who specialize in Wellness Lifestyle products and education.

 

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

 

About Resonate Blends, Inc. (OTCQB:KOAN)

Based in Calabasas, California, Resonate Blends, Inc. is a cannabis holding company centered on valued-added holistic Wellness and Lifestyle brands. The Company strategy is to ignite future growth by building a purpose-driven portfolio of research organizations, innovative and emerging brands, and retail channels. The holding Company’s focus is finding mutual value between product and consumer by optimizing quality, supply chain resources and financial performance. The Company offers a family of premium cannabis-based products of consistent quality based on unique formations calibrated to Resonate Blends effects system, one of the industry’s gold standard in user experience.

For more information please visit: www.resonateblends.com


Contact:

David Thielen Chief Investment Officer/Director Resonate Blends, Inc. david@resonateblends.com 571-888-0009


About Boustead Securities, LLC

Boustead Securities, LLC is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority-owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information visit please visit: www.boustead1828.com


Form CRS/Reg BI Disclaimer:

Boustead Securities, LLC, Sutter Securities Inc., and Sutter Securities Clearing,LLC (SSC) are registered with the Securities and Exchange Commission (SEC) as broker-dealers and are members of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC). Brokerage and investment advisory services and fees differ and it is important for you to understand these differences. Free and simple tools are available to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. When we provide you with a recommendation, we have to act in your best interest and not put our interest ahead of yours. At the same time, the way we make money creates a conflict with your interests. Please strive to understand and ask us about these conflicts because they can affect the recommendations we provide you. There are many risks involved with investing. For Boustead Securities customers and clients, please see our Regulation Best Interest Relationship Guide on the Form CRS Reg BI page on our website at https://www.boustead1828.com/form-crs-reg-bi. For Sutter Securities’ and Sutter Securities Clearing’s customers and clients, please see the Form CRS on the website at https://suttersecurities.com/wp-content/uploads/2020/12/Sutter-Form-CRS-combined-121020.pdf. For FlashFunders’ visitors, you may review the Form CRS of Boustead Securities, Sutter Securities and Sutter Securities Clearing under the Form CRS section. Please also carefully review and verify the accuracy of the information you provide us on account applications, subscription documents and others.


Forward-Looking Statements

This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur.


Boustead Securities, LLC (“Boustead”) client Know Labs, Inc. (“Know Labs” or the “Company”) (OTC: KNWN), an emerging leader in non-invasive medical diagnostics, announced an initial closing of $2,632,500 in a private placement to 36 accredited investors through a Regulation D 506(c) subordinated convertible note offering. 

The private placement consisted of convertible notes that bear annual interest of 8% and will be automatically converted to Common Stock at the lower of $1.00 per share on the one year anniversary or at a 25% discount to a Qualified Financing plus Warrants that were granted on a 1 to 0.5 basis (one-half Warrant for each full share of Common Stock into which the Convertible Notes are convertible). The Warrants have a five-year term and an exercise price equal to 120% of the per share conversion price of the Qualified Financing or other mandatory conversion.

The Company may continue offering additional Convertible Notes and Warrants on substantially the same terms until June 30, 2020 (unless extended at the discretion of the Company) or until the Company has raised a maximum of $5 million (unless increased at the discretion of the Company) in gross proceeds (or such other amount determined by the Company in its discretion).

Know Labs aims to create non-invasive biosensors capable of detecting and measuring biomolecules continuously. This has applications for a new area of personal health and medicine that may allow issues derived from abnormal blood glucose, hormone, medications, and metabolite levels to be discovered in real time. Know Labs has a foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place. 

In early April, Know Labs was granted a patent on its Bio-RFID™ technology, entitled “Health Related Diagnostics Employing Spectroscopy in Radio/Microwave Frequency Band.” Know Labs’ first focus with its Bio-RFID™ technology is the wearable non-invasive continuous monitoring of blood glucose levels, an important breakthrough for the diabetes community. The Company is making progress engineering the UBAND Continuous Glucose Monitor (CGM) into its market ready form for clinical trials later this year, the results of which will be submitted to the US Food and Drug Administration for approval.

Know Labs plans to initially enter the diabetic Continuous Glucose Monitoring (GDM) market with its UBAND non-invasive CGM product and to later enter the other clinical monitoring markets for continuous, non-invasive hormone, metabolite, and biomolecular monitoring. Each of these markets has eligible patent ranges in the millions, several potentially translating into significant market opportunities.

The Company’s announcement can be found here:



This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Clinical trials are in early stages.

 

About Know Labs, Inc. Know Labs, Inc. (OTC: KNWN) is a technology company that is developing and commercializing a completely new class of clinical non-invasive biosensors potentially capable of detecting and measuring – continuously and in real-time – biomolecules such as blood glucose, hormone levels, medications, and metabolites – to potentially usher in a new era of personal health and personalized medicine. Know labs has a foundational IP portfolio of 14 issued and 24 pending patents with an aggressive IP development plan in place. The executive team is comprised of technology inventors, technology/healthcare executives, and product developers responsible for leading Know Labs from a developmental-stage company to commercialization and scale. For more information, please visit www.knowlabs.co. About Boustead Securities, LLC Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com. About Sutter Securities Group, Inc. Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities Incorporated, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. Sutter Securities Group, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws.   SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com. Forward-Looking Statements This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.

bottom of page